| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 4,809,680 | 794,886 | ||
| Prepaid expenses and other current assets | 1,255,258 | 564,692 | ||
| Total current assets | 6,064,938 | 1,359,578 | ||
| Other assets | 32,094 | 33,200 | ||
| Total assets | 6,097,032 | 1,392,778 | ||
| Accounts payable | 1,104,184 | 1,481,949 | ||
| Accrued expenses and other current liabilities | 744,783 | 740,553 | ||
| Notes payable | 0 | 0 | ||
| Total liabilities | 1,848,967 | 2,222,502 | ||
| Common stock, 0.0001 par value 100,000,000 shares authorized 944,491 and 96,077 shares issued and outstanding at september30, 2025 and december31, 2024, respectively | 94 | 213 | ||
| Additional paid-in capital | 89,712,414 | 83,761,039 | ||
| Accumulated deficit | -85,464,443 | -84,590,976 | ||
| Total stockholders' equity | 4,248,065 | -829,724 | ||
| Total liabilities and stock holders' equity | 6,097,032 | 1,392,778 | ||
Salarius Pharmaceuticals, Inc. (SLRX)
Salarius Pharmaceuticals, Inc. (SLRX)